Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term

Core Viewpoint - The article discusses the Zacks Style Scores, which are designed to help investors identify stocks with the best chances of outperforming the market over the next 30 days, focusing on growth, momentum, and value characteristics. Group 1: Zacks Style Scores Overview - The Zacks Style Scores are categorized into four types: Growth Score, Momentum Score, Value Score, and VGM Score, each assessing different aspects of a stock's performance [2][10][19]. - Each stock is rated from A to F based on its value, growth, and momentum characteristics, with A being the highest score indicating a better chance of outperforming [9]. - The Style Scores are intended to complement the Zacks Rank, which is based on earnings estimate revisions, to aid in stock selection [5][20]. Group 2: Catalyst Pharmaceuticals (CPRX) Analysis - Catalyst Pharmaceuticals, Inc. (CPRX) is highlighted as a stock to watch, currently holding a Momentum Style Score of B and experiencing a 1.9% increase in share price over the past four weeks [6][16]. - CPRX has a Zacks Rank of 3 (Hold) and a VGM Score of A, indicating a solid position among stocks [15][16]. - For fiscal 2024, five analysts have revised their earnings estimates upwards, with the Zacks Consensus Estimate increasing by $0.10 to$2.02 per share, and CPRX has an average earnings surprise of 18% [24].